U.S. Food, 2018-05-21: FDA's 21 May 2018 letter to registered manufacturers asking them to relabel or stop distributing OTC oral benzocaine products because of the methemoglobinemia risk.
based on evidence that these products pose a serious and potentially fatal risk of methemoglobinemia to infants, children, and adults.
1
U.S. Food, 2018-05-21: FDA's 21 May 2018 letter to registered manufacturers asking them to relabel or stop distributing OTC oral benzocaine products because of the methemoglobinemia risk. C2. Dated May 21, 2018; addressed 'Dear CEO or President'. States the 1991 Oral Health Care Drug Products Tentative Final Monograph background and that the Agency intends further administrative action by rulemaking or OTC monograph reform. PDF page 1. Quote checked against pdftotext extraction of the PDF. Study type: regulatory record.
